279 related articles for article (PubMed ID: 19478038)
1. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
3. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
Abhishek A; Butt S; Gadsby K; Zhang W; Deighton CM
J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
[TBL] [Abstract][Full Text] [Related]
5. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
[TBL] [Abstract][Full Text] [Related]
6. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
7. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
11. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
Liang GC; Cordero M; Dyer A; Chang RW
J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
[TBL] [Abstract][Full Text] [Related]
12. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
13. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
[TBL] [Abstract][Full Text] [Related]
14. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
[TBL] [Abstract][Full Text] [Related]
15. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
16. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.
Hider SL; Tanveer W; Brownfield A; Mattey DL; Packham JC
Rheumatology (Oxford); 2009 Sep; 48(9):1152-4. PubMed ID: 19608723
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
